Wingammus

About the offering

rHEALTH Company Summary rHEALTH is a med-tech company based in Bedford, Massachusetts, developing a space-validated blood diagnostics platform for consumer and point-of-care use. The company has raised $23 million in funding to date and aims to bring lab-quality diagnostics from a single drop of blood to pharmacies, urgent care centers, and homes. The Problem Access to diagnostic testing remains centralized, requiring clinical labs, phlebotomists, and specialized equipment. This creates barriers to early detection, monitoring, and routine care—especially in remote, underserved, or home settings. Currently, 4.5 billion people globally have limited access to healthcare and diagnostic testing, 194 million U.S. adults have chronic conditions requiring diagnostic testing, lab results take 1-3 days on average, and physician interpretation takes 3-14 days. The Solution rHEALTH integrates miniaturized flow cytometry, AI, and multiplexed assay technology into a handheld device. The "rHEALTH Awesome" system enables rapid, decentralized testing across biomarkers, small molecules, and nucleic acids using a single drop of blood. The platform includes the rHEALTH Awesome device, test cartridges, a Health AI App for interpretation, and the SKYE Vitals Sensor for monitoring. Tests conventionally performed in central lab settings—blood counts, biomarkers, chemistry, coagulation, and nucleic acid tests—can be performed on the platform. Technology Validation The core technology was validated by NASA aboard the International Space Station, with astronaut Samantha Cristoforetti demonstrating the rHEALTH ONE blood sensor on-orbit. This space validation positions the technology to support astronaut health on Mars missions while enabling terrestrial point-of-care applications. Traction & Milestones The company has secured over $20 million in non-dilutive funding from NASA, NIH, and pharma partners, plus $3 million in equity financing. Additional highlights include $3 million in committed NIH funding for blood tests, winner of the $2.25 million Nokia Sensing XCHALLENGE, finalist in the $10 million Qualcomm Tricorder XPRIZE, 17 issued patents, first in-space dual-laser 5-channel cytometer, and a projected 1-year timeline to first FDA registration (forward-looking, no assurance of approval). Market Opportunity The Total Addressable Market (TAM) is $323 billion in global diagnostics and patient monitoring (2023), projected to exceed $400 billion by 2030. The Serviceable Addressable Market (SAM) is $224 billion covering global lab testing, point-of-care, and patient monitoring devices. The Serviceable Obtainable Market (SOM) is $16.2 billion, focused initially on hematology (complete blood count, coagulation analysis) plus 10% of patient monitoring. The Complete Blood Count alone represents 500 million tests annually in the U.S. Team CEO Eugene Y. Chan, MD holds a Harvard MD and graduated summa cum laude from Harvard. He is a physician-inventor honored by Esquire, MIT Technology Review, and XPRIZE, with 60+ patents and work subject to $200M+ in deals and exits. The team has regulatory expertise in ISO 13485 (required for FDA and CE mark approvals) and experience establishing multi-million dollar collaborations with government and pharma. Additional team members include Jamie Cheng (Assay QC Manager, Boston College biochemistry graduate, leads ISO 13485 compliance for IVD design) and Marcus Atkin (Industrial Designer with medical product development experience at Philips, IDEO, and Dyson). Current Fundraise rHEALTH is raising up to $1.23 million via Regulation Crowdfunding on StartEngine at $1.29 per share (Series CF Convertible Preferred Stock), implying a $99.82 million valuation. The minimum investment is $499.23, and the deadline is March 19, 2026. The campaign has raised $132,208 from 11 investors to date. Investor Perks Time-based early bird bonuses range from 3-10% bonus shares (within first 2 weeks) with branded merchandise and founder calls. Amount-based bonuses range from 2% ($500+) to 8% ($100,000+), with the top tier including a Zero-G flight ticket ($10K value). StartEngine Venture Club members receive an additional 10% bonus, and previous rHEALTH investors receive a 5% loyalty bonus. Important Regulatory Note rHEALTH products are currently in advanced stages of development and will require FDA approval prior to being available on the market. FDA review timelines are inherently uncertain, and there is no assurance regulatory approval will be obtained within stated timeframes or at all.

FAQ